Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?

Is RARE a good stock to buy? We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on r/ValueInvesting by u/Tallwhitedude123. Since the thesis was published on August 30^th, RARE shares have pulled back as a key pipeline setback shifted investor focus to whether its approved drugs can drive enough growth to offset the lost opportunity. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutical Inc.’s share was trading at $16.78 as of October 29^th...